Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
58.6M
-
Number of holders
-
164
-
Total 13F shares, excl. options
-
46.1M
-
Shares change
-
+6.37M
-
Total reported value, excl. options
-
$2.37B
-
Value change
-
+$326M
-
Put/Call ratio
-
1.34
-
Number of buys
-
108
-
Number of sells
-
-49
-
Price
-
$51.45
Significant Holders of AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO) as of Q2 2017
195 filings reported holding AGIO - AGIOS PHARMACEUTICALS, INC. - Common Stock as of Q2 2017.
AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO) has 164 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 46.1M shares
of 58.6M outstanding shares and own 78.66% of the company stock.
Largest 10 shareholders include FMR LLC (7.23M shares), WELLINGTON MANAGEMENT GROUP LLP (6.75M shares), VANGUARD GROUP INC (3.21M shares), Capital International Investors (3.13M shares), BB BIOTECH AG (2.87M shares), BlackRock Inc. (2.68M shares), Clearbridge Investments, LLC (1.53M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.5M shares), STATE STREET CORP (1.3M shares), and Invesco Ltd. (992K shares).
This table shows the top 164 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.